Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1401 ↗At a glance
Randomisierte kontrollierte Studie in Clinical Pharmacology in Drug Development, 2024. Written by Ekaterina Koksharova and 9 co-authors. Institution: Endocrinology Research Center, Moscow, Russia. Major MEDLINE topics: Glucose Clamp Technique, Cross-Over Studies, Blood Glucose, Insulin. Cited 6 times so far (Crossref); 20 references.
Abstract (original language)
The aim of the study was to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of T‐glu (GP40321, test drug), and reference insulin glulisine in a hyperinsulinemic‐euglycemic clamp procedure. During this study, 34 healthy male volunteers underwent the hyperinsulinemic‐euglycemic clamp procedure following subcutaneous 0.3 U/kg injection of T‐glu or reference insulin glulisine in a randomized, double‐blind, crossover study. Plasma glucose levels were monitored every 5 minutes for 8 hours. Glucose infusion rate adjustment was based on the blood glucose measurements. Evaluation of PD was performed using the glucose infusion rate values, while PK was calculated using insulin concentrations measured via enzyme‐linked immunosorbent assay. The study results showed that the 90% CI for the geometric mean ratios of primary PK and PD of T‐glu and reference insulin glulisine were within 80%‐125% comparability limits, and that the safety profiles were comparable. PK, PD, and safety similarity of T‐glu and reference insulin glulisine was demonstrated.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Endocrinology Research Center, Moscow, Russia.
- R&D Center, GEROPHARM, Saint-Petersburg, Russia.
- City Hospital No. 3, Yaroslavl, Russia.
Cite
APA
Koksharova, E., Drai, R., Noskov, S., Dorotenko, A., Protsenko, E., Radaeva, K., Arefeva, A., Gefen, M., Galstyan, G., & Makarenko, I. (2024). Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1401
Vancouver
Koksharova E, Drai R, Noskov S, Dorotenko A, Protsenko E, Radaeva K, et al. Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1401
BibTeX
@article{Koksharova2024,
author = {Koksharova, Ekaterina and Drai, Roman and Noskov, Sergei and Dorotenko, Artem and Protsenko, Ekaterina and Radaeva, Kseniia and Arefeva, Anna and Gefen, Maria and Galstyan, Gagik and Makarenko, Igor},
title = {Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1401}
}
EUVIMED